Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. This phase II, open-label, multicenter, randomized,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2012-01, Vol.18 (2), p.555-567
Hauptverfasser:	KIRKWOOD, John M, BASTHOLT, Lars, DUMMER, Reinhard, ROBERT, Caroline, SOSMAN, Jeff, LARKIN, James, HERSEY, Peter, MIDDLETON, Mark, CANTARINI, Mireille, ZAZULINA, Victoria, KEMSLEY, Karin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Alkylating - therapeutic use Benzimidazoles - therapeutic use Biological and medical sciences Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Dermatology Disease-Free Survival DNA Mutational Analysis Drug Substitution Female Humans Kaplan-Meier Estimate Male MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 2 - antagonists & inhibitors Medical sciences Melanoma - drug therapy Melanoma - genetics Melanoma - mortality Melanoma - pathology Middle Aged Mutation Neoplasm Staging Pharmacology. Drug treatments Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics Treatment Outcome Tumors of the skin and soft tissue. Premalignant lesions Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!